Scarica l'app Stockscreener
25.05
0.36%
-0.09
Dopo l'orario di chiusura:
25.07
0.02
+0.08%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché PFE Giù?
Forum
Previsione
Frazionamento azionario
Storia dei dividendi
Pfizer Inc Borsa (PFE) Ultime notizie
Pfizer Stock Near Lows But Analysts See Upside Ahead - TipRanks
The Pfizer-BioNTech COVID-19 Vaccine. Updated formulation keeps Comirnaty relevant - ad-hoc-news.de
Pfizer Paid Out $14.6 Billion in Dividends Over the Last 18 Months. Can It Keep This Up Through the Patent Cliff? - Yahoo Finance
Pfizer Paid Out $14.6 Billion in Dividends Over the Last 18 Months. Can It Keep This Up Through the Patent Cliff? - The Motley Fool
How the Pfizer building scare could push developers to rethink vertical conversion plans - The Real Deal
Pfizer Stock Leads 3 AI Healthcare Names Worth Further Research - simplywall.st
Pfizer stock holds support as shares await fresh catalyst - ad-hoc-news.de
Can Pfizer (NYSE:PFE) Strengthen Its Pipeline Story? - Kalkine Media
Engineers blame lack of steel reinforcement on Pfizer HQ structural failure - The Real Deal
Dividend Roundup: JPMorgan Chase, Coca-Cola, Johnson & Johnson, Pfizer, and more - Seeking Alpha
McDonald's vs. PfizerThe Better Retirement Stock Isn't the One You'd Guess - AOL.com
Analysts Have Conflicting Sentiments on These Healthcare Companies: Elevance Health (ELV) and Pfizer (PFE) - The Globe and Mail
Pfizer stock holds steady as recent earnings and pipeline updates shape investor expectations - ad-hoc-news.de
Pfizer (PFE) Could Be 16% Undervalued On New FDA Approval In Bladder Cancer - simplywall.st
Form 4 Pfizer For: 16 July By Investing.com - Investing.com Canada
EXCLUSIVE: Pfizer suspends sales of Premarin vaginal cream in India, citing supply challenges - Reuters
Pfizer Inc. stock outperforms competitors on strong trading day - MarketWatch
Exclusive-Pfizer suspends sales of Premarin vaginal cream in India, citing supply challenges - WTAQ
Pfizer (PFE) Stock Looks Fairly Priced With Pipeline Risks In View - Yahoo Finance
Pfizer Stock Below 50-Day and 200-Day SMA: Buy the Dip or Exit Now? - Yahoo Finance
Arbutus Biopharma (ABUS) Files Lawsuits Against Pfizer and BioNT - GuruFocus
Arbutus Files More Patent Infringement Suits Against Pfizer, BioNTech -- Update - marketscreener.com
Arbutus Files More Patent Infringement Suits Against Pfizer, BioNTech - marketscreener.com
Pfizer, BioNTech face global patent suits from Arbutus, Roivant over COVID vaccine tech - Seeking Alpha
Arbutus and Genevant file patent lawsuits against Pfizer, BioNTech - Investing.com
Arbutus Biopharma Files International Patent Lawsuits Against Pfizer and BioNTech, Announces Moderna Settlement Payment and Plans for Capital Return - Quiver Quantitative
Arbutus Initiates International Patent Infringement Enforcement Actions Against Pfizer and BioNTech, Receives First Payment From Moderna Settlement Agreement and Announces Intent to Return Capital to Shareholders - The Manila Times
Pfizer captive Blue Whale Re holds A rating amid hard market participation - Insurance Business
Pfizer stock holds steady as pipeline and patent cycle shape long-term outlook - ad-hoc-news.de
Pfizer Abrysvo by Pfizer Inc.RSV vaccine targets seniors and pregnant women - Ad Hoc News
Pfizer (NYSE:PFE) Faces New Patent Claim After $96 Billion in COVID Vaccine Revenue - TechStock²
Is Earlier‑Stage PADCEV‑Keytruda Approval Reshaping The Investment Case For Pfizer (PFE)? - simplywall.st
Sanofi sues Pfizer, Moderna over COVID shot technology - Reuters
Pfizer building’s column scare tests Midtown East’s biggest conversion bet - The Real Deal
Celcuity shares fall as launch delay eclipses US approval for breast cancer drug - Reuters
Sanofi Sues Moderna, Pfizer for Vaccine-Tech Patent Royalties - Bloomberg Law News
Pfizer (PFE) Announces FDA Approval of PADCEV plus Keytruda in MIBC - Yahoo Finance
AM Best Affirms Credit Ratings of Blue Whale Re Ltd. - Business Wire
Is the Bearishness Around Pfizer and Gilead Sciences a Contrarian Opportunity? - 24/7 Wall St.
Prevnar 13 by Pfizer Inc.pneumococcal vaccine quietly powering a key franchise - Ad Hoc News
PFE Stock Quote Price and Forecast - CNN
Pfizer’s EPS Has Fallen 65% From Its Peak, Here’s Why That Might Be the Point - TIKR.com
Sanofi Says Pfizer, Moderna COVID Jabs Infringe MRNA Tech - Law360
Structural Failure at Pfizer Conversion Project Triggers Citywide Construction Review - Propmodo
Pfizer (PFE) Wins FDA Approval For First Platinum Free Bladder Cancer Regimen - Yahoo Finance
How Pfizer Won Fed. Circ. Patent Dispute By 1 Carbon Atom - Law360
Pfizer (PFE) Stock Looks Fully Priced After Its 21% Slump - simplywall.st
A week after the old NYC Pfizer building buckled, what’s new? - PIX11
Pfizer Vs. Amgen: Bet That Pfizer's Seagen Integration Leads to Long-Term Oncology Alpha Over Amgen - 24/7 Wall St.
Pfizer Has the Highest-Yielding Dividend in the S&P 500. Should Investors Be Worried? - The Globe and Mail
Here's How Pfizer's Oncology Growth Story Looks Ahead of Q2 Results - Zacks Investment Research
Here's What to Expect From Pfizer's Next Earnings Report - Yahoo Finance
Donald Trump's Drug-Pricing Deals Are Reshaping Big Pharma -- Here's What That Means for Pfizer, AbbVie, and Bristol Myers Squibb - The Globe and Mail
Pfizer (NYSE:PFE) Holds 7% Yield as AI Selloff Hits, Options Traders Look for Protection - TechStock²
Pfizer (PFE) Advances While Market Declines: Some Information for Investors - Yahoo Finance Singapore
Can Pfizer (NYSE:PFE) Reinforce Its Value Stock Appeal? - Kalkine Media
Abbott Labs Vs. Pfizer: Which Discounted Healthcare Titan Screens as the Bigger Value Trap? - Yahoo Finance
Form 4 Pfizer For: 13 July By Investing.com - Investing.com Canada
Pfizer Building Scare Unlikely to Slow New York’s Residential-Conversion Fever - Realtor.com
Longevity Gene Therapy Holds in Aged Dogs: Pfizer COVID Vaccine LNP Partner Backs SIRT6 Platform - Tech Times
Pfizer Drops Patent Suit Over Alkem Copies of Inlyta Cancer Drug - Bloomberg Law News
Guggenheim cuts Pfizer stock price target to $35 on model update - Investing.com
BMO Capital Adjusts Price Target on Pfizer to $30 From $34, Maintains Outperform Rating - marketscreener.com
1.48%
0.67%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):